Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer
Authors Lv RB, Wang QG, Liu C, Liu F, Zhao Q, Han JG, Ren DL, Liu B, Li CL
Received 19 February 2017
Accepted for publication 5 July 2017
Published 14 August 2017 Volume 2017:10 Pages 4051—4057
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 5
Editor who approved publication: Dr XuYu Yang
Rong-Bin Lv,1,2 Qing-Gang Wang,2 Chao Liu,2 Fang Liu,2 Qing Zhao,3 Jian-Guo Han,2 Dao-Ling Ren,2 Bin Liu,2 Cheng-Li Li1
1Department of Interventional MRI, Shandong Medical Imaging Research Institute, Shandong University, Shandong, People’s Republic of China; 2Department of Nuclear Medicine, Taian City Central Hospital, Shandong, People’s Republic of China; 3Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
Aim: The aim of this study was to compare the efficacy and adverse effects of radioiodine (131I) therapy between two groups of patients with low-risk differentiated thyroid cancer (DTC) who received 30 mCi or 100 mCi radioiodine for ablation of the thyroid remnant after total thyroidectomy.
Methods: The study cohort was 173 patients, 85 of whom were given 30 mCi of radioiodine and the others were given 100 mCi of radioiodine. Follow-up involved neck ultrasonography, measurement of serum levels of thyroglobulin and whole-body scans to evaluate the response of radioiodine treatment. All patients were assessed for adverse effects.
Results: Of the 173 patients, 170 (98.3%) patients finally achieved successful ablation. The prevalence of successful ablation was 77.6% in the low-dose group versus 71.5% in the high-dose group after the first dose administration (P=0.36), 79% in the low-dose group versus 88% in the high-dose group after the second dose administration (P=0.416), and 97.6% in the low-dose group versus 98.9% in the high-dose group after the final ablation (P=0.54). We found no significant differences between the two groups. No patient had an adverse effect with a severity grade >2 and the prevalence of adverse effects in the high-dose group was higher than that in the low-dose group, especially for nausea, neck pain, and sore throat.
Conclusion: These data suggest that a low dose of radioiodine is as effective as a high dose of radioiodine for ablation of the thyroid remnant after total thyroidectomy for low-risk DTC. Moreover, low-dose radioiodine therapy is associated with a lower prevalence of adverse events.
Keywords: differentiated thyroid cancer, radioiodine, radiotherapy, thyroglobulin
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]